Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Blue Water Vaccines Inc

Healthcare US BWV

NoneUSD
0.00(0%)

Last update at 2024-04-09T03:57:48.085185Z

Day Range

--
LowHigh

52 Week Range

0.161.95
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap3.41M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.02517M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -13.41983M -3.41733M -1.59947M -0.82191M
Minority interest - - - -
Net income -13.29026M -3.41733M -1.57686M -0.76360M
Selling general administrative 9.35M 2.09M 1.10M 0.82M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.00675M 0.00489M 0.00306M 0.00057M
Ebit -13.48124M -3.41733M -1.62207M -0.88023M
Ebitda -13.54265M -3.41244M -1.61901M -0.87966M
Depreciation and amortization -0.06141M 0.00489M 0.00306M 0.00057M
Non operating income net other - - - -
Operating income -13.48124M -3.41733M -1.62207M -0.88023M
Other operating expenses 13.48M 3.42M 1.62M 0.88M
Interest expense 0.06M 0.00000M 0.02M 0.06M
Tax provision - - - -
Interest income - 0.00000M 0.02M 0.06M
Net interest income - 0.00000M 0.02M 0.06M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.12957M - -0.02260M -0.05832M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 13.48M 3.42M 1.62M 0.88M
Cost of revenue - - - -
Total other income expense net 0.06M - 0.02M 0.06M
Discontinued operations - - - -
Net income from continuing ops -13.41983M -3.41733M -1.59947M -0.82191M
Net income applicable to common shares -13.51619M -4.04472M -2.15939M -1.10188M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 26.31M 3.08M 4.81M 6.08M
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.47M 1.14M 0.28M 0.00001M
Total liab 3.92M 1.64M 0.08M 0.08M
Total stockholder equity 22.39M 1.45M 4.73M 6.00M
Deferred long term liab - - - -
Other current liab 2.42M 1.06M - 0.06M
Common stock 0.00016M 0.00003M 0.00003M 0.00003M
Capital stock 0.00016M 0.00004M 0.00004M 0.00004M
Retained earnings -19.37650M -5.95667M -2.53934M -0.93987M
Other liab - - 0.00964M 0.00686M
Good will - - - -
Other assets 0.04M - 0.20M 0.01M
Cash 25.75M 1.93M 4.31M 6.05M
Cash and equivalents - - - -
Total current liabilities 3.92M 1.64M 0.07M 0.08M
Current deferred revenue - - - -
Net debt -25.75266M -1.92847M -4.30882M -6.05075M
Short term debt - - - -
Short long term debt - - - -
Short long term debt total - - - -
Other stockholder equity 41.76M 7.40M 7.27M 6.94M
Property plant equipment 0.01M 0.01M 0.02M 0.00693M
Total current assets 26.26M 3.07M 4.60M 6.06M
Long term investments - - - -
Net tangible assets 22.39M 1.45M 4.73M 6.00M
Short term investments - - - -
Net receivables 0.04M 0.15M 0.00980M 0.00833M
Long term debt - - - -
Inventory - -0.15252M - -
Accounts payable 1.50M 0.58M 0.07M 0.02M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.04M - 0.20M 0.01M
Deferred long term asset charges - - - -
Non current assets total 0.05M 0.01M 0.22M 0.02M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.00934M -0.00192M -0.01179M -0.00450M
Change to liabilities 1.09M 0.34M 0.05M 0.02M
Total cashflows from investing activities -0.00934M -0.00192M -0.01179M -0.00450M
Net borrowings - - - -0.05462M
Total cash from financing activities 32.53M -0.33419M -0.33419M 6.88M
Change to operating activities 1.47M 0.99M -0.48238M -0.01710M
Net income -13.41983M -3.41733M -1.59947M -0.82191M
Change in cash 23.82M -2.38035M -1.74193M 6.05M
Begin period cash flow 1.93M 4.31M 6.05M 0.00000M
End period cash flow 25.75M 1.93M 4.31M 6.05M
Total cash from operating activities -8.69886M -2.04424M -1.73014M -0.82513M
Issuance of capital stock 34.87M - 0.00000M 6.93M
Depreciation 0.00675M 0.00489M 0.00306M 0.00057M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables -0.02333M -0.11496M -0.03648M -0.00833M
Sale purchase of stock -0.56681M - - -
Other cashflows from financing activities -1.76893M -0.33419M -0.01179M 6.93M
Change to netincome 2.18M 0.15M 0.33M 0.00327M
Capital expenditures 0.00934M 0.00192M 0.01M 0.00450M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 2.54M 1.21M -0.46857M -0.00705M
Stock based compensation 1.97M 0.13M 0.33M 0.00327M
Other non cash items 0.20M 0.02M - -
Free cash flow -8.70820M -2.04616M -1.74193M -0.82963M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BWV
Blue Water Vaccines Inc		 - -% - - - - 0.35 -0.4936
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Blue Water Vaccines Inc

201 East Fifth Street, Cincinnati, OH, United States, 45202

Key Executives

Name Title Year Born
Mr. Joseph Hernandez M.S., MBA CEO, Pres & Exec. Chairman 1973
Ms. Erin Henderson Chief Bus. Officer & Corp. Sec. 1975
Mr. Jon M. Garfield Chief Financial Officer 1964
Dr. Brian Price Ph.D. Head of Technology Strategy NA
Dr. Ronald R. Cobb Ph.D. Head of Science & Discovery NA
Mr. Andrew D. Skibo Ph.D. Global Head of Biologics Operations NA
Mr. Theodore Scott Yoho Head of Bus. Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions